Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 791-798

  Furfine, Eric S ^a,d   Baker, Christopher T ^b,e   Hale, Michael R ^b   Reynolds, David J ^a   Salisbury, Jo A ^a   Searle, Andy D ^c   Studenberg, Scott D ^a   Todd, Dan ^a   Tung, Roger D ^b   Spaltenstein, Andrew ^a  

^a GLAXOSMITHKLINE   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e Scion Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CACO-2 CELLS; CARBAMATES; DOGS; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; MASS SPECTROMETRY; PHOSPHORIC ACID ESTERS; PRODRUGS; RATS; RATS, WISTAR; SULFONAMIDES;

EID: 10744226866     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.791-798.2004     Document Type: Article

References (26)

1. Bangsberg, D. R., F. M. Hecht, E. D. Charlebois, A. R. Zolopa, M. Holodniy, L. Sheiner, J. D. Bamberger, M. A. Chesney, and A. Moss. 2000. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14:357-366.
2. Bartlett, J. A., R. DeMasi, J. Quinn, C. Moxham, and F. Rousseau. 2001. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 15:1369-1377.
3. Brodt, H. R., B. S. Kamps, P. Gute, B. Knupp, S. Staszewski, and E. B. Helm. 1997. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11:1731-1738.
4. Centers for Disease Control and Prevention. 1997. Update: trends in AIDS incidence - United States, 1996. Morb. Mortal. Wkly. Rep. 46:861-864.
5. Claxton, A. J., J. Cramer, and C. Pierce. 2001. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23:1296-1310.
6. Detels, R., A. Munoz, G. McFarlane, L. A. Kingsley, J. B. Margolick, J. Giorgi, L. K. Schrager, and J. P. Phair for the Multicenter AIDS Cohort Study Investigators. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 280:1497-1503.
7. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, A. Meibohm, J. H. Condra, F. T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E. A. Emini, J. A. Chodakewitz, R. Isaacs, and D. D. Richman. 2000. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133:35-39.
8. Haubrich, R., M. Thompson, R. Schooley, W. Lang, A. Stein, D. Sereni, M. E. van der Ende, F. Antunes, D. Richman, G. Pagano, L. Kahl, A. Fetter, D. J. Brown, N. Clumeck, and the Amprenavir PROAB 2002 Study Team. 1999. Phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS 13:2411-2420.
9. Haubrich, R. H., S. J. Little, J. S. Currier, D. N. Forthal, C. A. Kemper, G. N. Beall, D. Johnson, M. P. Dube, J. Y. Hwang, J. A. McCutchan, and the California Collaborative Treatment Group. 1999. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 13:1099-1107.
10. Hidalgo, I. J., T. J. Raub, and R. T. Borchardt. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
11. Hogg, R. S., K. V. Health, B. Yip, K. J. P. Cralb, M. V. O'Shaugnessy, M. T. Schechter, and J. S. G. Montaner. 1998. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279:450-454.
12. Kaplan, J. E., D. Hanson, M. S. Dworkin, T. Frederick, J. Bertolli, M. L. Lindegren, S. Holmberg, and J. L. Jones. 2000. Epidemiology of human immunodeficiency-virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30:S5-S14.
13. Kararli, T. T. 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16:351-380.
14. Le Moing, V., G. Chene, M. P. Carrieri, A. Alioum, F. Brun-Vezinet, L. Piroth, J. P. Cassuto, J.-P. Moatti, F. Raffi, C. Leport, and the Aproco Study Group. 2002. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16:21-29.
15. Low-Beer, S., B. Yip, M. V. O'Shaughnessy, R. S. Hogg, and J. S. Montaner. 2000. Adherence to triple therapy and viral load response. J. Acquir. Immune Defic. Syndr. 23:360-361.
16. Murphy, E. L., A. C. Collier, L. A. Kalish, S. F. Assmann, M. F. Para, T. P. Flanigan, P. N. Kuman, L. Mintz, F. R. Wallach, and G. J. Nemo for the Viral Activation Transfusion Study Investigators. 2001. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135:17-26.
17. Murphy, R. L., R. M. Gulick, V. DeGruttola, R. T. D'Aquila, J. J. Eron, J.-P. Sommadossi, J. S. Currier, L. Smeaton, I. Frank, A. M. Caliendo, J. G. Gerber, R. Tung, and D. R. Kuritzkes for the AIDS Clinical Trials Group 347 Study Team. 1999. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J. Infect. Dis. 179:808-816.
18. Opravil, M., R. W. Cone, M. Fischer, P. L. Vernazza, S. Bassetti, P. Lorenzi, L. R. Bisset, P. Ott, W. Huber, M. C. Knuchel, M. Roos, R. Luthy, R. Weber, and the Swiss HIV Cohort Study. 2000. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. J. Acquir. Immune Defic. Syndr. 23:17-25.
19. Pallela, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, and the HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
20. Paterson, D. L., S. Swindells, J. Mohr, M. Brester, E. N. Vergis, C. Squler, M. M. Wagener, and N. Singh. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133:21-30.
21. Raboud, J. M., M. Harris, S. Rae, J. S. Montaner, et al. 2002. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med. 3:118-124.
22. Saag, M. S., P. Tebas, M. Sension, M. Conant, R. Myers, S. K. Chapman, R. Anderson, and N. Clendeninn for the Viracept Collaborative Study Group. 2001. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 15:1971-1978.
23. Sadler, B. M., and D. S. Stein. 2002. Clinical pharmacology and pharmacokinetics of amprenavir. Ann. Pharmacother. 36:102-118.
24. Singh, N., S. M. Berman, S. Swindells, J. C. Justis, J. A. Mohr, C. Squier, and M. M. Wagener. 1999. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin. Infect. Dis. 29:824-830.
25. Stone, V. E. 2001. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin. Infect. Dis. 33:865-872.
26. Walmsley, S., B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, D. Johnson, R. Lalonde, A. Japour, S. Brun, and E. Sun for the M98-863 Study Team. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346:2039-2046.